The ATS Research Program provides seed funding for young investigators who seek cures and treatment for pulmonary diseases, critical care illnesses, and sleep disorders. This funding has transformed their professional lives, launching careers dedicated to scientific discovery and better patient care. The Research Program’s initial investment of $19.3 million has resulted in over $330 million in subsequent funds from the federal government to our awardees. That’s a return on investment of $17 per dollar awarded.
ATS Research Program awardees go on to establish laboratories where they publish their findings in the world’s leading journals… achieve leadership positions at prominent institutions… mentor the next generation of researchers and clinicians… and develop promising new treatments for complex lung diseases.
Darrell Kotton, MD
Dr. Kotton founded a 34-scientist Center for Regenerative Medicine at Boston University that is committed to “open-source biology.” It was among the first to derive induced pluripotent stem cells from patients with lung disease.
Caroline Owen, MD, PhD
Dr. Owen, a senior molecular biologist, Brigham and Women’s Hospital, has received $5 million in grants to study at a molecular level COPD, acute lung injury, interstitial lung diseases, asthma, and bacterial and viral lung infections.
Charles Powell, MD
Dr. Powell, now chief of pulmonary, critical care, and sleep medicine at Mount Sinai Hospital and CEO of the Mount Sinai-National Jewish Health Respiratory Institute, is advancing understanding of the factors that increase genetic susceptibility to lung cancer.
The ATS Research Program gives patients hope and launches careers in medicine and science. We’re proud of these accomplishments but we want to do more.
